ISAL 2019 | Developments in newly diagnosed AML therapy in Europe: inspiring cooperation for tailored treatment

Bob Löwenberg

Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses developments in newly diagnosed acute myeloid leukemia (AML) therapy in Europe from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Löwenberg explains how these new therapies may replace or add value to the standard 7+3 chemotherapy backbone, and highlights the need for multinational cooperation to recruit sufficient numbers of patients to trials.

Share this video